(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence.

S005 Figure 1

Ima Paydar, MD, Todd DeWees, PhD, Matthew Powell, MD, David Mutch, MD, Perry W. Grigsby, MD, MS, Julie K. Schwarz, MD, PhD; Washington University School of Medicine

Objective: To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence.

Materials and Methods: The medical records of 62 patients treated with adjuvant radiotherapy at Washington University School of Medicine following surgical staging for endometrial cancer (total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, and lymph node dissection) were reviewed. Twenty-six were treated with a combination of external beam radiotherapy and vaginal brachytherapy (EBRT + VB), and 36 patients were treated with postoperative vaginal brachytherapy (VB) alone. Median follow-up for all patients was 48 months.

Results: Median patient age was 61 years (range: 30–87 yr). All tumors had endometrioid histology. There were 30 grade 1 tumors, 20 grade 2 tumors, and 12 grade 3 tumors. For all patients, the 5-year overall survival was 75.4%, and the 5-year recurrence-free survival was 89%. There was no statistically significant difference in overall survival (P = .770) or freedom from vaginal (P = .981), pelvic (P = .834), distant (P = .307), or any recurrence (P = .230) with respect to modality of treatment (EBRT + VB vs VB alone) (Figure). In the multivariate analysis, the only risk factor influencing overall survival was patient age (P = .033). Four patients experienced a toxicity requiring hospital admission, and all of these patients were treated with pelvic external beam plus brachytherapy.

Conclusions: Vaginal brachytherapy alone results in excellent local control for patients with stage II endometrial cancer after surgical staging. Long-term toxicities are rare and are more common in patients who are treated with pelvic external beam plus brachytherapy.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content